Latorre Marcos R, Albergo José I, Farfalli Germán L, Roitman Pablo D, Plantalech Luisa, Ayerza Miguel A, Aponte-Tinao Luis A
Instituto de Ortopedia y Traumatología, Carlos E. Ottolenghi, Buenos Aires, Argentina. E-mail:
Instituto de Ortopedia y Traumatología, Carlos E. Ottolenghi, Buenos Aires, Argentina.
Medicina (B Aires). 2021;81(5):767-773.
Giant cell tumor of bone is an intermediate, locally aggressive and rarely metastasizing, primary bone neoplasia. In recent years denosumab emerged as a treatment alternative for this pathology. The objective of this work was to analyze its indications as well as the clinical outcomes, side effects and local recurrence rates in patients diagnosed with giant cell tumor of bone, who received denosumab as neoadjuvant treatment. Between 2010 and 2018, 80 patients with giant cell tumor were analyzed, of whom 14 received denosumab as a neoadjuvant treatment. The minimum follow-up was 12 months. In 8 patients it was a primary tumor, while 6 showed tumor recurrence. In all cases, clinical improvement was evident. Thirteen patients presented radiographic changes, and 11 showed complete histological response. A local recurrence was evidenced in 6 of 14 patients, and at least one adverse effect related to denosumab (including tumor malignancy) was identified in 7. Despite being a useful tool for treating giant cell tumor, the use of denosumab is associated with a higher rate of local recurrences and is not free of adverse effects.
骨巨细胞瘤是一种中间型、局部侵袭性且很少发生转移的原发性骨肿瘤。近年来，地诺单抗成为治疗这种疾病的一种替代方法。这项工作的目的是分析其在接受地诺单抗作为新辅助治疗的骨巨细胞瘤患者中的适应证以及临床疗效、副作用和局部复发率。2010年至2018年期间，对80例骨巨细胞瘤患者进行了分析，其中14例接受地诺单抗作为新辅助治疗。最短随访时间为12个月。8例为原发性肿瘤，6例出现肿瘤复发。在所有病例中，临床改善都很明显。13例患者出现影像学改变，11例显示完全组织学缓解。14例患者中有6例出现局部复发，7例发现至少一种与地诺单抗相关的不良反应（包括肿瘤恶性变）。尽管地诺单抗是治疗骨巨细胞瘤的一种有用工具，但使用地诺单抗与较高的局部复发率相关，且并非没有不良反应。
